ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report)’s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $95.77 and traded as high as $110.08. ProShares Ultra Nasdaq Biotechnology shares last traded at $108.73, with a volume of 12,726 shares.
ProShares Ultra Nasdaq Biotechnology Price Performance
The stock has a market cap of $87.15 million, a PE ratio of 20.68 and a beta of 1.20. The company’s fifty day moving average is $96.37 and its 200-day moving average is $87.75.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
A number of institutional investors have recently modified their holdings of the stock. Kaizen Financial Strategies lifted its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 4.7% in the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock valued at $483,000 after buying an additional 250 shares during the period. Citadel Advisors LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the third quarter worth about $307,000. Finally, Franklin Resources Inc. acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the second quarter worth about $32,000.
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Featured Stories
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
